The Library
Low serum cartonectin/CTRP3 concentrations in newly diagnosed type 2 diabetes mellitus : in vivo regulation of cartonectin by glucose
Tools
Tools
Tools
Ban, Bo, Bai, Bo, Zhang, Manman, Hu, Jiamiao, Ramanjaneya, Manjunath, Tan, Bee K. and Chen, Jing (2014) Low serum cartonectin/CTRP3 concentrations in newly diagnosed type 2 diabetes mellitus : in vivo regulation of cartonectin by glucose. PLoS One, 9 (11). pp. 1-5. e112931. doi:10.1371/journal.pone.0112931
|
PDF
WRAP_journal.pone.0112931.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (392Kb) | Preview |
Official URL: http://dx.doi.org/10.1371/journal.pone.0112931
Abstract
Objectives:
Cartonectin is a novel adipokine of the C1q complement/TNF-related protein (CTRP) superfamily, with glucose lowering effects, anti-inflammatory and cardio-protective properties. We sought to investigate circulating cartonectin concentrations in subjects with type 2 diabetes mellitus (T2DM) as well as age and BMI matched control subjects. We also examined the effects of a 2 hour 75 g oral glucose tolerance test (OGTT) on serum cartonectin concentrations in T2DM subjects.
Design:
Cross-sectional study [newly diagnosed (first discovery, not on any treatments) T2DM (n = 47) and control (n = 63) subjects]. Serum cartonectin was measured by ELISA.
Results:
Serum cartonectin concentrations were significantly lower in patients with T2DM compared to controls (P<0.05). Furthermore, serum cartonectin was significantly negatively correlated with glucose and CRP, and significantly positively correlated with leptin, in all subjects (n = 110). When subjected to multiple regression analysis, none of these variables were predictive of serum cartonectin (P>0.05). There were no significant correlations in T2DM subjects (n = 47). In control subjects (n = 63), serum cartonectin was significantly negatively correlated with CRP, and significantly positively correlated with insulin, HOMA-IR and leptin. However, when subjected to multiple regression analysis, none of these variables were predictive of serum cartonectin (P>0.05). Finally, serum cartonectin concentrations were significantly lower in T2DM subjects after a 2 hour 75 g OGTT (P<0.01).
Conclusions:
Cartonectin may serve as a novel biomarker for the prediction and early diagnosis of T2DM patients. Furthermore, cartonectin and/or pharmacological agents that increase circulating cartonectin levels can represent a new therapeutic field in the treatment of T2DM patients. Further research is needed to clarify these points.
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
